AbbVie (NYSE: ABBV), a leading pharmaceutical company in the US, has licensed to Canada-based Enigma Biomedical Group (EBG) its cutting-edge F18 PET imaging biomarkers. These biomarkers are designed to detect the presence of four-repeat (4R) tau protein in patients who may have neurodegenerative diseases. The agreement holds potential for aiding in the design of treatments for conditions such as progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). EBG will conduct the initial evaluation and validation of these innovative PET ligands, with the option to secure exclusive development and commercialization licenses.- Flcube.com
Recent news:
-
Sino Biopharmaceutical Submits NDA for Anlotinib and Penpulimab Combo in HCC to NMPA -
Sihuan Pharmaceutical's Huisheng Pharm Strikes Exclusive Deal for Semaglutide Biosimilar in China -
Innovent Biologics' IBI354 Earns Breakthrough Therapy Designation for Ovarian Cancer Treatment -
CDE Includes Double-Crane's Hydroxocobalamine and Sanofi Genzyme's Fitusiran in Rare Disease Care Plan -
Apeiron Therapeutics Initiates Phase Ia/B Study for GTA182 in Solid Tumors with MTAP Deficiency
